~~<i id='04292BF7A9'><strike id='04292BF7A9'><tt id='04292BF7A9'><pre id='04292BF7A9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

focus

author：Wikipedia 2025-09-30 09:31:16 - browse：816

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： House looks to weaken Medicare negotiation

leisure time

hotspot

explore

focus

knowledge

SophieGogginsoftheNationalMuseumsScotlandinEdinburghviewsDollytheSheepduringtheopeningofamajornewdev

WSS

'A game

Medical device lobby: We're tired of waiting on Medicare coverage

Covid isolation guidance eased by the CDC

Transgender sports debate: Physicians say bans are health issue

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Biotech companies concerned about China biosecurity crackdown

entertainment

focus

leisure time

Guidelines to prevent youth baseball injuries need more muscle

Information blocking fines are now fair game in health care

What does generative AI mean for health care? We asked experts

Midwives could help bridge maternal health disparities in the U.S.

Medical records are filled with copy

FDA weighs limits of animal data in assessing artificial wombs

BioMarin wins approval for gene therapy to treat hemophilia A

Kenai launches with $82 million for Parkinson’s stem cell therapy

Guidelines to prevent youth baseball injuries need more muscle

FogPharma raises $145 million in rare Series E round

hotspot

Senate bill would ban some hospital facility fees

Medicare to pay more for cardiac rehab in hospital outpatient clinics

RaDonda Vaught to speak at CommonSpirit event on patient safety

Medical device lobby: We're tired of waiting on Medicare coverage

Akili changes sales model for its ADHD video game treatment

Assistant physicians can help address the primary care shortage

hotspot

explore

focus

knowledge